Trial intelligence / Profile preview

IMMbrace: Risankizumab vs Methotrexate in Plaque Psoriasis

NCT03219437Phase 3Completed

Sponsor
AbbVie Inc.
Start
Jul 2018
Primary completion
Nov 2021
Modality
Monoclonal Antibodies
Countries
1
01

Overview

A Phase 3 trial of risankizumab in plaque psoriasis, sponsored by AbbVie Inc.. Started Jul 2018; status: completed.

02

Drugs

risankizumab
03

Conditions

plaque psoriasis

Beyond the preview

Go deeper on NCT03219437.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT03219437.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call